MedTrace Logo

LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

NCT07733076 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-07-30

No results posted yet for this study

Summary

Single center, single arm study to evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

Conditions

  • Peripheral Arterial Disease

Interventions

DEVICE

LineMatrix® Biological Vascular Graft

LineMatrix® Biological Vascular Graft for Infrarenal Arterial Bypass or Replacement

Sponsors & Collaborators

  • Humatrix Medical Technology (Suzhou) Co., LTD

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-09-30
Completion
2028-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07733076 on ClinicalTrials.gov